Serologic Testing for Rubella
In the early- to mid-20th century, Rubella continued to be an important public health concern, causing hundreds of thousands of cases in the United States, and millions of cases of acute Rubella and Congenital Rubella Syndrome worldwide.
However, in 1969, a Rubella vaccine was licensed for use with the target population of children aged 1 year to puberty. Implementation of this vaccine resulted in a 78% reduction in cases from 1969-1976. In 1978, the target population was expanded to include adolescents and postpubertal females in an attempt to further decrease the number of cases of Congenital Rubella Syndrome. In 1979, a new formulation of the vaccine was introduced and this formulation yielded a more pronounced and prolonged immune response. A decade later, the U.S. Department of Health and Human Services established a goal, and this goal was to eliminate indigenous Rubella and CRS in the United States. This initiative was accompanied by the routine implementation of the 2-dose MMR vaccination series in the United States.
Timeline to Elimination
Jump to section: